Lenalidomide-Dexamethasone or Melphalan-Lenalidomide-Prednisone (MPR) or Cyclophosphamide-Prednisone-Lenalidomide (CPR) for Initial treatment of Real Life Elderly Patients with Newly Diagnosed Multiple Myeloma

significant accumulation of the NuRD complex at MYC TSS after IMiDs exposure. Importantly, CHD4 silencing attenuated lenalidomide induced MYC transcriptional repression and cell death. In summary, our studies suggest that IKZF1 drives MYC expression in MM by regulating the activity of the IGH 3’ enhancer and preventing the repositioning of the NURD complex to its promoter. 5. Multiple Myeloma Therapy in Newly Diagnosed Patients excluding Transplantation